School of Engineering
Chemical & Synthetic Biology for Biotherapies
(ChemSynBio)
In the ChemSynBio group (Chemical & Synthetic Biology for Biotherapies) we combine the power of chemical and synthetic biology to create protein-based precision therapeutics and biomedical tools. Our main goals are to treat brain tumors and other brain diseases, and to understand and improve drug transport across the blood-brain barrier.
ChemSynBio investiga y trabaja en transferencia de tecnología en la siguientes áreas:
- Development of bio- and nano- therapeutics, especially to treat brain tumors.
- Engineering and chemistry of antibodies, proteins, and peptides for biomedical applications.
- Study and engineering of transport systems to cross the blood-brain barrier.
- Development of conditionally-active proteins.
- Generation of new proteins through library selections and directed evolution.
COORDINATOR:
Benjamí Oller-Salvia, PhD
Associate Professor - Junior Leader F. La Caixa - ERC Grantee
+34932672000
SEE MORE
MEMBERS:
EXTERNAL COLABORATORS
Dr. Sally Ward
University of Southampton
Dr. Manuel Valiente
Centro Nacional de Investigaciones Oncológicas (CNIO)
Dr. David Baker
University of Washington
DEPARTAMENTO DE BIOINGENIERÍA IQS
Roberta Lucchi, Maria C Lucana, Montserrat Escobar, Pol Martín, Pedro Canhao, Adrià Puigdemont, Burcu Yaldiz
FACILITIES
Biotherapies Laboratory
LINKED NEWS
Interview
Interview with Montse Escobar, IQS Predoctoral Researcher
01/12/2023
Montse Escobar has earned an INPhINIT grant awarded by the "la Caixa" Foundation to carry out her doctoral thesis within the Bioengineering Department at IQS. This represents the first INPhINIT grant awarded to the school.
READ FULL NEW
Interview
Producing masked antibodies through targeted evolution
01/09/2022
“In the ADC2GBM project, we're combining our experience in targeted evolution and antibody engineering to develop activatable antibody-drug conjugates for the treatment of glioblastoma multiforme”
READ FULL NEW
Research
New Peptide and Protein Characterization and Purification Instruments
18/05/2022
IQS has acquired three chromatography instruments for peptide and protein characterization and purification, with funding from the Fundación “la Caixa” Junior Leader Fellowships programme.
READ FULL NEW
7 Questions for...
Cristina Díaz
12/05/2022
Interview to Dr Cristina Díaz, researcher with the GEMAT group at the IQS School of Engineering.
READ FULL NEW
Research
Activatable antibodies in targeted therapies
18/02/2022
Dr Oller from IQS has recently received a grant from the Semilla programme with the Spanish Cancer Society (AECC) to work on new types of activatable antibodies against a specific marker of resistant cancer cells.
READ FULL NEW
Research
Activatable Antibodies to Increase Selectivity for Brain Tumour Therapies
19/10/2021
In the Materials Engineering Group (GEMAT) at the IQS School of Engineering, the team led by Dr Benjami Oller Salvia is working to take on two of the great challenges with GBM therapies.
READ FULL NEW
LATEST PROJECTS
OBGate (Creating an orthogonal gate to the brain)
Change of paradigm in the the field of brain delivery: opening a new Orthogonal Brain Gate where targeted drugs will be able to cross the blood brain barrier for the treatment of brain diseases
Funding Agency:
Research Group Link:
Materials Engineering (GEMAT)
Chemical & Synthetic Biology for Biotherapies (ChemSynBio)
APTIBody (Nanoterapias de Glioma)
Estrategia para generar anticuerpos activables y su aplicación para dirigir nanoterapias génicas a células madre de glioma
Funding Agency:
Research Group Link:
Materials Engineering (GEMAT)
Chemical & Synthetic Biology for Biotherapies (ChemSynBio)
PRO-ANTIBODY (Activación selectiva de Anticuerpos contra el Glioblastoma)
Desarrollo de anticuerpos activables para la administración de terapias génicas en las células madre de glioma
Funding Agency:
Research Group Link:
Materials Engineering (GEMAT)
Chemical & Synthetic Biology for Biotherapies (ChemSynBio)
